A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

681

Participants

Timeline

Start Date

May 21, 2021

Primary Completion Date

July 29, 2025

Study Completion Date

May 10, 2027

Conditions
Clear Cell Renal Cell Carcinoma
Interventions
BIOLOGICAL

Nivolumab and rHuPH20

Specified dose on specified days

BIOLOGICAL

Nivolumab

Specified dose on specified days

Trial Locations (89)

0

Local Institution - 0005, Santiago

Local Institution - 0060, Tallaght

1023

Local Institution - 0053, Auckland

3204

Local Institution - 0041, Hamilton

4414

Local Institution - 0078, Palmerston North

5000

Local Institution - 0079, Parana

5800

Local Institution - 0030, Río Cuarto

6189

Local Institution, Nice

7600

Local Institution - 0058, Mar del Plata

14080

Local Institution - 0089, Tlalpan

14263

Local Institution - 0025, Buffalo

18081

Local Institution - 0106, Praha 8 Liben

19611

Local Institution - 0088, West Reading

20133

Local Institution, Milan

20141

Local Institution - 0018, Milan

26100

Local Institution - 0033, Cremona

27010

Local Institution - 0101, Torreón

27100

Local Institution - 0092, Pavia

28026

Local Institution - 0072, Madrid

28033

Local Institution - 0067, Madrid

28046

Local Institution - 0074, Madrid

28050

Local Institution - 0075, Madrid

31013

Local Institution - 0059, Seville

33521

Local Institution - 0017, Tampere

34098

Local Institution - 0019, Istanbul

34284

Local Institution - 0035, Istanbul

35128

Local Institution - 0014, Padua

39008

Local Institution - 0086, Santander

43126

Local Institution - 0082, Parma

47014

Local Institution - 0027, Meldola

50134

Local Institution - 0008, Florence

60611

Local Institution, Chicago

64460

Local Institution - 0103, Monterrey

64710

Local Institution - 0031, Monterrey

76000

Local Institution - 0065, Querétaro

76090

Local Institution - 0085, Querétaro

77900

Local Institution - 0020, Olomouc

78200

Local Institution - 0105, San Luis Potosí City

92151

Local Institution - 0051, Suresnes

94800

Local Institution - 0068, Villejuif

125284

Hertzen Moscow Oncology Research Center, Moscow

153040

Ivanovo Regional Oncology Dispensary, Ivanovo

197022

LLC Eurocityclinic, Saint Petersburg

200347

Local Institution - 0016, Craiova

400132

Local Institution - 0002, Cluj-Napoca

400641

Local Institution - 0040, Cluj-Napoca

454087

SBIH Chelyabinsk Regional Clinical Centre of Oncology and Nuclear Medicine, Chelyabinsk

603000

Local Institution, Nizghiy Novgorod

644013

Budgetary Healthcare Institution of Omsk Region - Clinical Oncological Dispensary, Omsk

2520598

Local Institution - 0077, Viña del Mar

7500653

Local Institution - 0104, Santiago

7500921

Local Institution - 0076, Santiago

C1419AHN

Local Institution - 0095, Capital Federal

B2700CPM

Local Institution - 0037, Pergamino

R8500ACE

Local Institution - 0066, Viedma

C1426ANZ

Local Institution - 0038, Buenos Aires

J5402DIL

Local Institution - 0056, San Juan

80520-174

Local Institution - 0064, Curitiba

98700-000

Local Institution - 0107, Ijuí

91350-200

Local Institution - 0039, Porto Alegre

014784-000

Local Institution - 0071, Barretos

15090-000

Local Institution - 0070, São José do Rio Preto

20230-130

Local Institution - 0090, Rio de Janeiro

01246-000

Local Institution - 0081, São Paulo

01327-0001

Local Institution - 0096, São Paulo

Unknown

Local Institution - 0084, Temuco

656 53

Local Institution - 0063, Brno

500 05

Local Institution - 0036, Hradec Králové

708 52

Local Institution - 0099, Ostrava

140 59

Local Institution - 0010, Prague

00168

Local Institution - 0100, Roma

00152

Local Institution - 0091, Rome

05100

Local Institution - 0057, Terni

21-500

Local Institution - 0055, Biała Podlaska

85-796

Local Institution - 0062, Bydgoszcz

80-214

Local Institution - 0083, Gdansk

30-688

Local Institution - 0021, Krakow

31-115

Local Institution - 0098, Krakow

60-569

Local Institution - 0001, Poznan

02-781

Local Institution - 0023, Warsaw

3030-075

Local Institution - 0050, Coimbra

1500-650

Local Institution - 0052, Lisbon

022238

Local Institution - 0024, Bucharest

08003

Local Institution - 0048, Barcelona

08035

Local Institution - 0102, Barcelona

08041

Local Institution - 0049, Barcelona

08208

Local Institution - 0032, Sabadell

06230

Local Institution - 0026, Ankara

06590

Local Institution - 0097, Ankara

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT04810078 - A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread | Biotech Hunter | Biotech Hunter